This data is encouraging as it reinforces the large and growing body of evidence indicating that certepetide can enhance the targeting, penetration, and effectiveness of therapeutic agents - in this ...
Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the ...
The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.
GSK acquires exclusive rights from Syndivia for antibody-drug conjugate in prostate cancer: London, UK Tuesday, October 28, 2025, 09:00 Hrs [IST] GSK plc and Syndivia, a private b ...
GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...
Sanofi has developed a simpler way to create site-specific antibody-to-mannose-6-phosphate (M6P) conjugates that eliminates the need for enzyme remodeling. This more straightforward method makes M6P ...
EMA grants Orphan Drug Designation to GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 to treat pulmonary neuroendocrine carcinoma: London, UK Wednesday, October 29, 2025 ...
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback